Two of these, ciltacabtagene autoleucel and idecabtagene vicleucel, are second-generation CAR-T cell products which target B-cell maturation antigen (BCMA) in multiple myeloma.35,36. This evidence concerns the gene TNFRSF17 and AL amyloidosis.